Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/6/2023 | $29.00 → $38.00 | Hold → Buy | Truist |
| 4/11/2023 | $25.00 | Market Perform | SVB Securities |
| 4/4/2023 | $27.00 | Overweight | Piper Sandler |
| 2/15/2023 | $35.00 → $22.00 | Buy → Hold | Jefferies |
| 8/1/2022 | $30.00 | Buy → Hold | Truist |
| 7/27/2022 | $21.00 → $35.00 | Hold → Buy | Jefferies |
| 6/27/2022 | $30.00 → $34.00 | Buy | Canaccord Genuity |
| 2/2/2022 | $30.00 | Buy | Canaccord Genuity |
SC 13G/A - CORCEPT THERAPEUTICS INC (0001088856) (Subject)
SC 13G/A - CORCEPT THERAPEUTICS INC (0001088856) (Subject)
SC 13G/A - CORCEPT THERAPEUTICS INC (0001088856) (Subject)
Truist upgraded Corcept Therapeutics from Hold to Buy and set a new price target of $38.00 from $29.00 previously
SVB Securities initiated coverage of Corcept Therapeutics with a rating of Market Perform and set a new price target of $25.00
Piper Sandler initiated coverage of Corcept Therapeutics with a rating of Overweight and set a new price target of $27.00
Corcept Therapeutics Incorporated (NASDAQ:CORT) today announced it will report fourth quarter and full-year 2024 financial results and provide a corporate update on February 26, 2025. The company will also host a conference call that day at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time). Conference Call Information Participants must register in advance of the conference call by clicking here. Upon registering, each participant will receive a dial-in number, and a unique access PIN. Each access PIN will accommodate one caller. Additionally, a listen-only webcast will be available by clicking here. A replay of the call will be available on the Investors / Events tab of Corcept.com.
Corcept Therapeutics Incorporated (NASDAQ:CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, has submitted a new drug application (NDA) to the U.S. Food and Drug Administration for its proprietary, selective cortisol modulator, relacorilant, to treat patients with endogenous hypercortisolism (Cushing's syndrome). Corcept's NDA is based on positive results from the pivotal GRACE trial and confirmatory evidence from the Phase 3 GRADIENT and long-term extension studies and a Phase 2 study in hypercortisolism. Patients in these
Results from Phase 3 long-term extension study of relacorilant to treat patients with hypercortisolism were presented at the World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC) 116 patients with hypercortisolism were enrolled with treatment duration of up to six years Results provide further evidence of relacorilant's potential benefit as a treatment for patients with hypercortisolism Corcept Therapeutics Incorporated (NASDAQ:CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, presented r
144 - CORCEPT THERAPEUTICS INC (0001088856) (Subject)
144 - CORCEPT THERAPEUTICS INC (0001088856) (Subject)
8-K - CORCEPT THERAPEUTICS INC (0001088856) (Filer)
Corcept Therapeutics Incorporated (NASDAQ:CORT) today announced it will report fourth quarter and full-year 2024 financial results and provide a corporate update on February 26, 2025. The company will also host a conference call that day at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time). Conference Call Information Participants must register in advance of the conference call by clicking here. Upon registering, each participant will receive a dial-in number, and a unique access PIN. Each access PIN will accommodate one caller. Additionally, a listen-only webcast will be available by clicking here. A replay of the call will be available on the Investors / Events tab of Corcept.com.
Revenue of $182.5 million, a 48 percent increase over the same period in 2023 Increase in 2024 revenue guidance to $675 – $700 million, from $640 – $670 million Net income per common share of $0.41 (diluted), compared to $0.28 in third quarter 2023 Cash and investments of $547.6 million as of September 30, 2024 Results from Phase 3 GRADIENT trial support findings from pivotal Phase 3 GRACE study; new drug application (NDA) of relacorilant to be submitted this quarter Corcept Therapeutics Incorporated (NASDAQ:CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by mod
Corcept Therapeutics Incorporated (NASDAQ:CORT) today announced it will report third quarter financial results and provide a corporate update on October 30, 2024. The company will also host a conference call that day at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time). Conference Call Information Participants must register in advance of the conference call by clicking here. Upon registering, each participant will receive a dial-in number, and a unique access PIN. Each access PIN will accommodate one caller. Additionally, a listen-only webcast will be available by clicking here. A replay of the call will be available on the Investors / Events tab of Corcept.com. About Corcept Therapeutic
MENLO PARK, Calif., Jan. 29, 2024 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ:CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced the appointment of Roberto Vieira as President, Oncology. He will report to Joseph K. Belanoff, MD, Corcept's Chief Executive Officer, and join the company's Executive Team. Mr. Vieira joins Corcept from Mirati Therapeutics, Inc., where he served as Senior Vice President of U.S. Commercial until earlier this month. At Mirati, Mr. Vieira built the U.S. commercial o
MENLO PARK, Calif., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ:CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrine, oncology, metabolism, and neurology disorders by modulating the effects of the hormone cortisol, today announced the appointment of Monica Tellado as President, Emerging Markets. She will report to Joseph K. Belanoff, MD, Corcept's Chief Executive Officer, and join the company's Executive Team. Ms. Tellado's prior role was at Heartflow, where she served as Chief Financial Officer. Before joining Heartflow, Ms. Tellado spent 19 years in ascending leadership roles at Gilead Science
MENLO PARK, Calif., April 07, 2022 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ:CORT), a commercial-stage company engaged in the discovery and development of drugs to treat severe endocrine, metabolic, oncologic and neurological disorders by modulating the effects of the hormone cortisol, today announced the appointment of three individuals to Commercial and Development leadership roles. Daniel Einhorn, MD, FACP, FACE, has joined Corcept as Vice President, Endocrine Strategy; Amiel Balagtas has joined as Vice President, Development Operations; and Lyndah Dreiling, MD, has joined as Vice President, Global Oncology Development. Dr. Einhorn will report to Sean Maduck, Presid
5 - CORCEPT THERAPEUTICS INC (0001088856) (Issuer)
4 - CORCEPT THERAPEUTICS INC (0001088856) (Issuer)
4 - CORCEPT THERAPEUTICS INC (0001088856) (Issuer)